Rare side effect of adjuvant ipilimumab after surgical resection of melanoma: Guillain-Barré syndrome.
Guillain-Barré syndrome is a life-threatening neurological disorder that presents with rapid ascending paralysis and areflexia. Guillain-Barré syndrome is traditionally associated with infections from a gastrointestinal or respiratory tract source. We report the case of a 71-year-old man with melanoma who was treated with ipilimumab as adjuvant immunotherapy and subsequently developed Guillain-Barré syndrome. The diagnosis was made clinically through physical exam findings. He was successfully treated with a combination of intravenous immunoglobulin therapy and corticosteroids.
['Patel|Rohini J|RJ|', 'Liu|Michael A|MA|', 'Amaraneni|Akshay|A|', 'Sindhu|Simran K|SK|']
D000276:Adjuvants, Immunologic D000368:Aged D003937:Diagnosis, Differential D020275:Guillain-Barre Syndrome D006801:Humans D016756:Immunoglobulins, Intravenous D000074324:Ipilimumab D008297:Male D008545:Melanoma D012878:Skin Neoplasms
cancer intervention chemotherapy peripheral nerve disease skin cancer unwanted effects / adverse reactions